Please assess the completion status of the following clinical trial:

Trial Title: PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have histologically or cytologically confirmed clear cell renal cell carcinoma (RCC)~* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension and is ≥ 1.0 cm by spiral CT scan~* No prior treatment except~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy \> 6 months~* Good/intermediate Motzer prognostic status~* ANC ≥ 1,000/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10.0 g/dL~* Total bilirubin ≤ 2.0 mg/dL~* AST and ALT \< 2.5 times normal~* Creatinine ≤ 1.8 mg/dL OR creatinine clearance \> 50 mL/min~* Calcium \< 12 mg/dL (when corrected for serum albumin)~* INR \< 1.5 times upper limit of normal~* Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% by 2D echo~* Pulse oximetry ≥ 90% at rest on room air~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* No evidence of bleeding diathesis~* No uncontrolled coagulation disorders~* No active infections requiring IV antibiotics~* No known HIV, hepatitis C, or hepatitis B~* No autoimmune disease requiring ongoing therapy~* No requirement for adrenal replacement~* No angina (controlled or uncontrolled)~* No uncontrolled hypertension~* No history of other major medical illnesses including, but not limited to, any of the following:~  * Cardiac ischemia~ * Myocardial infarction~ * Major cardiac arrhythmias~ * Inflammatory bowel disorders~* No other prior malignancy except for previously treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 3 years~* No significant psychiatric disease that, in the opinion of the principal investigator, would preclude giving adequate informed consent or render immunotherapy unsafe~PRIOR CONCURRENT THERAPY:~* No prior treatment for RCC except sunitinib malate~  * Patients may have progressed or have been intolerant to sunitinib malate~* No prior systemic treatment for metastatic disease (other than sunitinib malate)~* No prior organ allografts~* At least 2 weeks since prior laparoscopic/robotic surgery~* At least 4 weeks since prior open nephrectomy~* More than 4 weeks since prior and no concurrent radiotherapy or other surgery~* More than 4 weeks since prior systemic steroids~* More than 2 weeks since prior topical, injected, or inhaled steroids~* No concurrent steroid therapy~* No concurrent Hypericum perforatum (St. John's wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginterferon alfa-2b (Type: EXPERIMENTAL): Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues